These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 3285132

  • 1. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia.
    Segawa M, Hirata Y, Fujimori S, Okada K.
    Metabolism; 1988 May; 37(5):454-60. PubMed ID: 3285132
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Adv Exp Med Biol; 1979 May; 119():347-56. PubMed ID: 115231
    [No Abstract] [Full Text] [Related]

  • 3. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y, Fujimori S, Okada K.
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [Abstract] [Full Text] [Related]

  • 4. Evidence for existence of polyol pathway in cultured rat mesangial cells.
    Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y.
    Diabetes; 1987 Feb; 36(2):240-3. PubMed ID: 3100369
    [Abstract] [Full Text] [Related]

  • 5. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
    Horie S, Nagai H, Yuuki T, Narita Y, Tsuda Y, Nakajima T, Nakamura N.
    J Diabetes Complications; 1998 Feb; 12(3):163-9. PubMed ID: 9618072
    [Abstract] [Full Text] [Related]

  • 6. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.
    Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA.
    Diabetes; 1983 Nov; 32(11):988-92. PubMed ID: 6416910
    [Abstract] [Full Text] [Related]

  • 7. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.
    Sredy J, Sawicki DR, Notvest RR.
    J Diabet Complications; 1991 Nov; 5(1):42-7. PubMed ID: 1830318
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS, Engerman RL.
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [Abstract] [Full Text] [Related]

  • 12. Analysis of sorbitol, galactitol, and myo-inositol in lens and sciatic nerve by high-performance liquid chromatography.
    Miwa I, Kanbara M, Wakazono H, Okuda J.
    Anal Biochem; 1988 Aug 15; 173(1):39-44. PubMed ID: 3189800
    [Abstract] [Full Text] [Related]

  • 13. The role of polyols in the pathophysiology of hypergalactosemia.
    Berry GT.
    Eur J Pediatr; 1995 Aug 15; 154(7 Suppl 2):S53-64. PubMed ID: 7671966
    [Abstract] [Full Text] [Related]

  • 14. Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes?
    Willars GB, Lambourne JE, Tomlinson DR.
    Diabetes; 1987 Dec 15; 36(12):1425-31. PubMed ID: 3678622
    [Abstract] [Full Text] [Related]

  • 15. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK, Hanwell MA, Satchell PM, Handelsman DJ, Turtle JR.
    Metabolism; 1984 Dec 15; 33(12):1119-22. PubMed ID: 6438438
    [Abstract] [Full Text] [Related]

  • 16. Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
    Hotta N, Nakamura J, Sakakibara F, Hamada Y, Hara T, Mori K, Nakashima E, Sasaki H, Kasama N, Inukai S, Koh N.
    Am J Physiol; 1997 Nov 15; 273(5):E965-71. PubMed ID: 9374683
    [Abstract] [Full Text] [Related]

  • 17. Relation of Na+, K(+)-ATPase to delayed motor nerve conduction velocity: effect of aldose reductase inhibitor, ADN-138, on Na+, K(+)-ATPase activity.
    Hirata Y, Okada K.
    Metabolism; 1990 Jun 15; 39(6):563-7. PubMed ID: 2161992
    [Abstract] [Full Text] [Related]

  • 18. Glutathione depletion in the lens of galactosemic and diabetic rats.
    Lou MF, Dickerson JE, Garadi R, York BM.
    Exp Eye Res; 1988 Apr 15; 46(4):517-30. PubMed ID: 3133235
    [Abstract] [Full Text] [Related]

  • 19. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL, Kern TS.
    Diabetes; 1993 Jun 15; 42(6):820-5. PubMed ID: 8495805
    [Abstract] [Full Text] [Related]

  • 20. Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats.
    Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Naruse K, Sasaki H, Mizuno K, Matsubara A, Kakuta H.
    Exp Physiol; 1995 Nov 15; 80(6):981-9. PubMed ID: 8962712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.